Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral
Phase 2Active 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Multiple Myeloma
Conditions
Newly Diagnosed Multiple Myeloma
Trial Timeline
Oct 20, 2021 → Dec 1, 2028
NCT ID
NCT04891809About Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral
Isatuximab-Irfc 20 MG/ML [Sarclisa] + Lenalidomide + Dexamethasone Oral is a phase 2 stage product being developed by Sanofi for Newly Diagnosed Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT04891809. Target conditions include Newly Diagnosed Multiple Myeloma.
What happened to similar drugs?
0 of 5 similar drugs in Newly Diagnosed Multiple Myeloma were approved
Approved (0) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04891809 | Phase 2 | Active |
Competing Products
18 competing products in Newly Diagnosed Multiple Myeloma